Reaction of Müller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine
- PMID: 20206241
- DOI: 10.1016/j.brainresbull.2010.02.011
Reaction of Müller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine
Abstract
The aim of this study was to evaluate the reaction of Müller cells in an experimental rat model of intraocular pressure (IOP) and their response to treatment with ocular hypotensive drugs. Episcleral vein cauterization in unilateral eyes of Wistar rats was performed to produce elevated IOP. The animals were divided into five groups: control, experimental, and experimental treated with timolol, latanoprost or brimonidine. Histological sections of retina were studied by immunochemistry with antibodies to glial fibrillary acidic protein (GFAP), and the percentage of labeled area was measured to evaluate the degree of reactive gliosis. In the experimental group, the Müller cells showed hypertrophy and a significant increase in GFAP (4.39+/-0.32%) in relation to retinas of the control group (2.05+/-0.14%). Gliosis was detected in all three treated groups, with a varying increase in GFAP intensity. The timolol-treated group showed the most intense and persistent glial reactivity after 3 months of treatment (13.89+/-0.63%). Treatment with brimonidine, however, resulted in a decrease in the level of GFAP immunoreactivity (8.37+/-0.4%). The group treated with latanoprost showed the lowest glial reactivity (4.8+/-0.36%). Given that all three drugs are effective hypotensive agents, their neuroprotective effect could be related with other factors, such as gliosis, which, over long periods may have noxious effects on the neurons. Thus, hypotensives like brimonidine, and specially latanoprost, may afford greater neuroprotection to the ganglion cells by attenuating the retinal glial reaction.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension.Invest Ophthalmol Vis Sci. 2001 Nov;42(12):2849-55. Invest Ophthalmol Vis Sci. 2001. PMID: 11687528
-
Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2917-23. doi: 10.1167/iovs.05-1253. Invest Ophthalmol Vis Sci. 2006. PMID: 16799034 Clinical Trial.
-
Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments.Exp Eye Res. 2008 May;86(5):798-806. doi: 10.1016/j.exer.2008.02.008. Epub 2008 Mar 4. Exp Eye Res. 2008. PMID: 18394603
-
Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans.Arch Ophthalmol. 1999 May;117(5):673-4. doi: 10.1001/archopht.117.5.673. Arch Ophthalmol. 1999. PMID: 10326968 Review. No abstract available.
-
Potential roles of astrocytes and Müller cells in the pathogenesis of glaucoma.J Pharmacol Sci. 2021 Mar;145(3):262-267. doi: 10.1016/j.jphs.2020.12.009. Epub 2020 Dec 31. J Pharmacol Sci. 2021. PMID: 33602506 Review.
Cited by
-
Tyrosinase is the modifier of retinoschisis in mice.Genetics. 2010 Dec;186(4):1337-44. doi: 10.1534/genetics.110.120840. Epub 2010 Sep 27. Genetics. 2010. PMID: 20876567 Free PMC article.
-
Long-term evaluation of retinal morphology and function in a mouse model of oxygen-induced retinopathy.Mol Vis. 2020 Apr 1;26:257-276. eCollection 2020. Mol Vis. 2020. PMID: 32256029 Free PMC article.
-
Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma.Cell Death Dis. 2014 Jul 17;5(7):e1341. doi: 10.1038/cddis.2014.306. Cell Death Dis. 2014. PMID: 25032864 Free PMC article.
-
Retinal ganglion cell loss is accompanied by antibody depositions and increased levels of microglia after immunization with retinal antigens.PLoS One. 2012;7(7):e40616. doi: 10.1371/journal.pone.0040616. Epub 2012 Jul 26. PLoS One. 2012. PMID: 22848388 Free PMC article.
-
Novel Therapeutics in Glaucoma Management.Curr Neuropharmacol. 2018;16(7):978-992. doi: 10.2174/1570159X15666170915142727. Curr Neuropharmacol. 2018. PMID: 28925883 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous